← Back to Search

Cancer Vaccine

Pneumovax 23- pneumococcal polysaccharide for Type 1 Diabetes

Phase 4
Waitlist Available
Led By Ana Creo, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months post vaccination
Awards & highlights

Study Summary

This trial looks at whether kids with type 1 diabetes have a strong enough immune response to the PPSV23 vaccination, and what might affect that response.

Eligible Conditions
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months post vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months post vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Immunoglobulin G (IgG) Antibodies

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pneumovax 23Experimental Treatment2 Interventions
Type 1 Diabetes subjects will receive Pneumovax 23-pneumococcal polysaccharide (PPSV23)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blood draw
2021
Completed Phase 4
~6290
Pneumovax 23- pneumococcal polysaccharide
2021
Completed Phase 4
~30

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,239 Previous Clinical Trials
3,771,570 Total Patients Enrolled
Ana Creo, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
23 Total Patients Enrolled
~7 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top